Purified EMD Protein Composition Depleted of Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Enamel Matrix Derivative (EMD) compositions for dental and pharmaceutical applications contain proteinase inhibitors like α1-antichymotrypsin and Fetuin A, which reduce their effectiveness in promoting hard tissue proliferation and differentiation, and mineralization.
Innovation Solution
A composition depleted of α1-antichymotrypsin and Fetuin A, comprising purified EMD proteins with molecular weights between 1 and 55 kDa and iso-electric points between 5.5 and 11, or proteins with molecular weights between 56 and 160 kDa and iso-electric points between 3-10, is developed to enhance hard tissue regeneration and mineralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EMD composition contains proteinase inhibitors like α1-antichymotrypsin and Fetuin A, then the composition maintains stability and prevents unwanted proteolysis, but the effectiveness in promoting hard tissue proliferation, differentiation, and mineralization is reduced
Solution Approach 1:
The patent removes specific proteinase inhibitors (α1-antichymotrypsin and Fetuin A) from the EMD composition through purification processes. This extraction of harmful components resolves the contradiction by eliminating substances that inhibit osteoblast differentiation and hard tissue formation, while retaining the beneficial EMD proteins that promote regeneration.
Solution Approach 2:
The patent modifies the compositional parameters of EMD by controlling the presence and concentration of specific proteins. By adjusting the purity level and removing specific inhibitor proteins through controlled purification steps, the composition achieves enhanced osteogenic activity while maintaining structural stability of the remaining EMD components.
2Productivity
If EMD composition is purified to remove proteinase inhibitors, then hard tissue regeneration effectiveness is improved, but the complexity of the purification process increases
Solution Approach 1:
The patent divides the complex purification process into distinct sequential steps, each targeting specific protein components. This segmentation allows for systematic removal of proteinase inhibitors while preserving beneficial EMD proteins, making the overall complex process manageable and controllable through multiple specialized purification stages.
Solution Approach 2:
The patent employs multiple purification steps that progressively change compositional parameters, such as protein concentration, molecular weight distribution, and specific protein ratios. Each purification step modifies these parameters to progressively remove inhibitors while enriching therapeutic components, achieving high purity through cumulative parameter optimization.
Data Source
Figure 1A~1
Figure 2
Figure 3A
AI summary
The present invention relates to an improved pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55kDa, formulated in a suitable pharmaceutical carrier. The present invention further relates to an improved pharmaceutical, dental and/or cosmetic composition comprising purified Enamel Matrix Derivative (EMD) proteins, which is depleted of proteins which have a molecular weight between 56 and 160kDa and an iso-electric point between 3-10. The improved pharmaceutical, dental and/or cosmetic composition of the present invention comprises purified Enamel Matrix Derivative (EMD) proteins, which are depleted of proteinase inhibitors, such as α1-antichymotrypsin and/or Fetuin A. Said improved composition is herein preferably intended to be used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.